The Medical Advisor

Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: August 2026 Quick Answer:  Cancer treatment is moving from a one-size-fits-all model toward increasingly biomarker-driven, immune-based, targeted and combination therapy . The most consequential 2026 cancer breakthrough is daraxonrasib , an oral RAS(ON) inhibitor that nearly doubled overall survival in previously treated metastatic pancreatic cancer in the phase 3 RASolute 302 trial presented at ASCO 2026. Other major advances include the OPTIMA trial , showing many high-risk breast cancer patients can safely skip chemotherapy after genomic testing; the bispecific antibody ivonescimab , which outperformed standard immunotherapy in squamous lung cancer; continued expansion of CAR-T and cell therapies into solid tumors; and growing, evidence-tiered interest in repurposed drugs and metabolic approaches as complementary strategies. AACR 2026 and ASCO 2026 both emphasized that progress ...

CAR T-cell therapy (Chimeric Antigen Receptor T-Cell) is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.” This article provides a comprehensive list of CAR-T therapy companies worldwide. Read on to learn more about innovative CAR-T cell therapy companies and the technologies they are using to fight cancer. CAR-T Cell Therapy Industry In 1987, Israeli immunologist Dr. Zelig Eshhar from the Weizmann Institute of Science developed the first “chimeric antigen receptor” (CAR), laying the foundation for modern CAR-T cell therapy. CARs are synthetic, engineered receptor proteins designed in the laboratory and do not exist naturally in the human body. Chimeric antigen receptor (CAR) T-cell therapy involves genetically modifying a patient’s own T cells to express these engineered receptors, e...